• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Lexeo Therapeutics Inc.

    5/14/25 12:00:47 PM ET
    $LXEO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $LXEO alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 4)


    LEXEO THERAPEUTICS, INC.

    (Name of Issuer)


    Common Stock

    (Title of Class of Securities)


    52886X107

    (CUSIP Number)


    03/31/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    52886X107


    1Names of Reporting Persons

    JANUS HENDERSON GROUP PLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    JERSEY
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    4,557,920.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    4,557,920.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    4,557,920.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    13.7 %
    12Type of Reporting Person (See Instructions)

    IA, HC


    SCHEDULE 13G

    CUSIP No.
    52886X107


    1Names of Reporting Persons

    Janus Henderson Biotech Innovation Master Fund Ltd
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    MASSACHUSETTS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    2,683,874.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    2,683,874.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    2,683,874.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    8.1 %
    12Type of Reporting Person (See Instructions)

    IV


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    LEXEO THERAPEUTICS, INC.
    (b)Address of issuer's principal executive offices:

    345 PARK AVENUE SOUTH, FLOOR 6 NEW YORK, NY 10010
    Item 2. 
    (a)Name of person filing:

    Janus Henderson Group plc
    (b)Address or principal business office or, if none, residence:

    201 Bishopsgate EC2M 3AE, United Kingdom
    (c)Citizenship:

    Y9
    (d)Title of class of securities:

    Common Stock
    (e)CUSIP No.:

    52886X107
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    JHIUS may be deemed to be the beneficial owner of 4,553,050 shares
    (b)Percent of class:

    13.7  %
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    0

     (ii) Shared power to vote or to direct the vote:

    4553050

     (iii) Sole power to dispose or to direct the disposition of:

    0

     (iv) Shared power to dispose or to direct the disposition of:

    4553050

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    N/A
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.


    JHIUS, JHIUKL and JHIAIFML are indirect subsidiaries of Janus Henderson and are registered investment advisers furnishing investment advice to Managed Portfolios.
    Item 8.Identification and Classification of Members of the Group.
     
    If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group.


    N/A
    Item 9.Notice of Dissolution of Group.
     
    Notice of dissolution of a group may be furnished as an exhibit stating the date of the dissolution and that all further filings with respect to transactions in the security reported on will be filed, if required, by members of the group, in their individual capacity. See Item 5.


    N/A

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    JANUS HENDERSON GROUP PLC
     
    Signature:Kristin Mariani
    Name/Title:Head of North America Compliance, CCO
    Date:05/14/2025
     
    Janus Henderson Biotech Innovation Master Fund Ltd
     
    Signature:Kristin Mariani
    Name/Title:Head of North America Compliance, CCO
    Date:05/14/2025
    Exhibit Information

    POWER OF ATTORNEY The undersigned, Janus Henderson Group plc ("the Company"), does hereby make, constitute and appoint each of Kristin Mariani and Caroline Barotti acting severally, as its true and lawful attorneys in-fact, for the purpose of, from time to time, executing in its name and on its behalf, whether the Company individually or as representative of others, any and all documents, certificates, instruments, statements, other filings and amendments to the foregoing (collectively, "documents") determined by such person to be necessary or appropriate to comply with ownership or control-person reporting requirements imposed by any United States or non-United States governmental or regulatory authority, including, without limitation, Forms 13D, 13F, 13G and 13H and any amendments to any of the foregoing as may be required to be filed with the Securities and Exchange Commission, and delivering, furnishing or filing any such documents with the appropriate governmental, regulatory authority or other person, and giving and granting to each such attorney-in-fact power and authority to act in the premises as fully and to all intents and purposes as the Company might or could do if personally present by one of its authorized signatories, hereby ratifying and confirming all that said attorney-in-fact shall lawfully do or cause to be done by virtue hereof. Any such determination by an attorney-in-fact named herein shall be conclusively evidenced by such person's execution, delivery, furnishing or filing of the applicable document. This power of attorney shall be valid from the date hereof and shall remain in full force and effect until either revoked in writing by the Company, or, in respect of any attorney-in-fact named herein, until such person ceases to be an employee of the Company or one of its affiliates. IN WITNESS WHEREOF, the undersigned has caused this power of attorney to be executed as of this 9th day of December, 2022. Janus Henderson Group plc By: /s/ Michelle Rosenberg Name: Michelle Rosenberg Title: General Counsel and Company Secretary

    Get the next $LXEO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $LXEO

    DatePrice TargetRatingAnalyst
    6/13/2024$28.00Outperform
    Robert W. Baird
    6/6/2024$22.00Buy
    H.C. Wainwright
    11/28/2023$20.00Overweight
    JP Morgan
    11/28/2023$20.00Buy
    Stifel
    11/28/2023$19.00Outperform
    Leerink Partners
    11/28/2023$22.00Outperform
    RBC Capital Mkts
    11/28/2023$23.00Buy
    Chardan Capital Markets
    More analyst ratings

    $LXEO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Medical Officer Adler Eric sold $1,623 worth of shares (585 units at $2.77), decreasing direct ownership by 0.86% to 67,681 units (SEC Form 4)

      4 - Lexeo Therapeutics, Inc. (0001907108) (Issuer)

      5/20/25 5:00:14 PM ET
      $LXEO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Legal Officer Robertson Jenny sold $1,445 worth of shares (521 units at $2.77), decreasing direct ownership by 0.82% to 63,098 units (SEC Form 4)

      4 - Lexeo Therapeutics, Inc. (0001907108) (Issuer)

      5/20/25 5:00:12 PM ET
      $LXEO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Executive Officer Townsend Richard Nolan sold $2,979 worth of shares (1,074 units at $2.77), decreasing direct ownership by 0.48% to 221,173 units (SEC Form 4)

      4 - Lexeo Therapeutics, Inc. (0001907108) (Issuer)

      5/20/25 5:00:15 PM ET
      $LXEO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $LXEO
    Financials

    Live finance-specific insights

    See more
    • Lexeo Therapeutics Announces Positive Interim Data for LX1001, First-Ever Gene Therapy to Impact the Underlying Genetic Cause of APOE4-Associated Alzheimer's Disease, at the Clinical Trials on Alzheimer's Disease (CTAD) Conference

      Dose-dependent increase in neuroprotective APOE2 expression in all participants with ongoing durability at 12 months Consistent reductions across CSF tau biomarkers and tau PET in majority of participants LX1001 well tolerated across all dose cohorts with no reports of amyloid-related imaging abnormalities (ARIA) Company to host webcast today at 7:00 AM ET NEW YORK, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (NASDAQ:LXEO), a clinical stage genetic medicine company dedicated to pioneering treatments for genetically defined cardiovascular diseases and APOE4-associated Alzheimer's disease, today announced positive interim results from the Phase 1/2 study of LX1001

      10/30/24 6:14:00 AM ET
      $LXEO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Lexeo Therapeutics Announces Investor Webcast to Report Interim Phase 1/2 Clinical Data of LX2006 for the Treatment of Friedreich Ataxia Cardiomyopathy on Monday, July 15, 2024

      NEW YORK, July 11, 2024 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (NASDAQ:LXEO), a clinical stage genetic medicine company dedicated to pioneering treatments for genetically defined cardiovascular diseases and APOE4-associated Alzheimer's disease, today announced that the company will conduct an investor webcast on Monday, July 15, 2024, at 8:00 AM ET to provide an interim clinical data update on LX2006, an AAVrh10.hFXN gene therapy for the treatment of Friedreich ataxia (FA) cardiomyopathy. The presentation will include an overview of the natural history of FA cardiomyopathy and summary of clinically meaningful endpoints, interim data from Lexeo's ongoing SUNRISE-FA Phase 1/2 clinical

      7/11/24 8:00:00 AM ET
      $LXEO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $LXEO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Lexeo Therapeutics Announces $80 Million Equity Financing to Further Advance Development of Transformative Genetic Medicines for Cardiovascular Diseases

      Cash runway extended into 2028; capital proceeds to fund operations through potential 2027 efficacy readout for LX2006 in Friedreich ataxia cardiomyopathy Financing led by Frazier Life Sciences and Janus Henderson Investors with participation from new and existing investors NEW YORK, May 27, 2025 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (NASDAQ:LXEO), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, today announced it has entered into a securities purchase agreement with a select group of institutional and healthcare accredited investors to issue and sell an aggregate of 20,790,120 shares ("Shares") of its common sto

      5/27/25 7:31:10 AM ET
      $LXEO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Lexeo Therapeutics Reports First Quarter 2025 Financial Results and Operational Highlights

      Announced positive interim data for LX2006 from Phase 1/2 studies in Friederich ataxia (FA) cardiomyopathy; frataxin expression and LVMI improvement exceeded co-primary target thresholds for planned registrational study LX2006 registrational study expected to begin by early 2026; commencing enrollment in prospective natural history study, CLARITY-FA, in Q2 2025 to serve as concurrent external control Phase 1/2 clinical trial of LX2020 (HEROIC-PKP2) currently enrolling patients in Cohort 3; interim clinical data update on track for second half of 2025 Redeployed $20 million to focus on clinical-stage programs; cash, cash equivalents and investments of $106.9 million expected to prov

      5/12/25 7:00:00 AM ET
      $LXEO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Lexeo Therapeutics to Present New CMC Data at the 28th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting

      NEW YORK, May 01, 2025 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (NASDAQ:LXEO), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, announced today that new data supporting its AAV manufacturing approach will be presented at the 28th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) taking place May 13-17, 2025 in New Orleans, LA. "The data being presented at ASGCT underscore the strength of our industry-leading capabilities in AAV manufacturing with high yield and high quality," said José Manuel Otero, Chief Technical Officer of Lexeo Therapeutics. "Scientists at Lexeo have optimized a manufacturing platfo

      5/1/25 9:16:04 AM ET
      $LXEO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $LXEO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $LXEO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Robert W. Baird initiated coverage on Lexeo Therapeutics with a new price target

      Robert W. Baird initiated coverage of Lexeo Therapeutics with a rating of Outperform and set a new price target of $28.00

      6/13/24 7:10:25 AM ET
      $LXEO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • H.C. Wainwright initiated coverage on Lexeo Therapeutics with a new price target

      H.C. Wainwright initiated coverage of Lexeo Therapeutics with a rating of Buy and set a new price target of $22.00

      6/6/24 7:17:54 AM ET
      $LXEO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • JP Morgan initiated coverage on Lexeo Therapeutics with a new price target

      JP Morgan initiated coverage of Lexeo Therapeutics with a rating of Overweight and set a new price target of $20.00

      11/28/23 7:29:52 AM ET
      $LXEO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Lexeo Therapeutics Inc.

      SC 13G/A - Lexeo Therapeutics, Inc. (0001907108) (Subject)

      11/14/24 5:49:30 PM ET
      $LXEO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Lexeo Therapeutics Inc.

      SC 13G/A - Lexeo Therapeutics, Inc. (0001907108) (Subject)

      11/14/24 4:45:58 PM ET
      $LXEO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Lexeo Therapeutics Inc.

      SC 13G/A - Lexeo Therapeutics, Inc. (0001907108) (Subject)

      11/14/24 12:32:15 PM ET
      $LXEO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $LXEO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Cholmondeley Paula H bought $104,852 worth of shares (15,000 units at $6.99), increasing direct ownership by 96% to 30,627 units (SEC Form 4)

      4 - Lexeo Therapeutics, Inc. (0001907108) (Issuer)

      11/26/24 5:00:06 PM ET
      $LXEO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $LXEO
    SEC Filings

    See more
    • SEC Form DEFA14A filed by Lexeo Therapeutics Inc.

      DEFA14A - Lexeo Therapeutics, Inc. (0001907108) (Filer)

      6/5/25 4:52:05 PM ET
      $LXEO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SCHEDULE 13G filed by Lexeo Therapeutics Inc.

      SCHEDULE 13G - Lexeo Therapeutics, Inc. (0001907108) (Subject)

      6/4/25 4:51:58 PM ET
      $LXEO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SCHEDULE 13G filed by Lexeo Therapeutics Inc.

      SCHEDULE 13G - Lexeo Therapeutics, Inc. (0001907108) (Subject)

      6/4/25 4:04:18 PM ET
      $LXEO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $LXEO
    Leadership Updates

    Live Leadership Updates

    See more
    • Lexeo Therapeutics Appoints Kyle Rasbach as Chief Financial Officer

      NEW YORK, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (NASDAQ:LXEO), a clinical stage genetic medicine company dedicated to pioneering treatments for genetically defined cardiovascular diseases and APOE4-associated Alzheimer's disease, today announced that Dr. Kyle Rasbach has been appointed Chief Financial Officer, effective immediately. Dr. Rasbach brings a wealth of life sciences experience to the company and joins ahead of multiple anticipated catalysts across its gene therapy programs. "Kyle has an exceptional track record as an operator and life sciences portfolio manager, and we are excited to welcome him to Lexeo at a time when we are advancing our pipeline and tran

      12/19/24 7:00:00 AM ET
      $LXEO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Lexeo Therapeutics Provides Update on Cardiac Portfolio and Reports Third Quarter 2024 Financial Results

      Reached alignment with FDA on key elements of registrational development plan for LX2006, including accelerated approval pathway with left-ventricular mass index (LVMI) and frataxin protein expression as co-primary registrational endpoints Received RMAT designation for LX2006 for the treatment of Friedreich ataxia (FA) cardiomyopathy, potentially enabling expedited development and increased interaction with the FDA Completed enrollment of LX2006 SUNRISE-FA Phase 1/2 trial, with four participants treated in cohort 3; total of 16 participants dosed with LX2006 to date across SUNRISE-FA and Weill Cornell trials Completed enrollment of cohort 1 of LX2020 HEROIC-PKP2 Phase 1/

      11/13/24 7:30:00 AM ET
      $LXEO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Lexeo Therapeutics Reports Second Quarter 2024 Financial Results and Operational Highlights

      Announced positive interim data from Phase 1/2 studies in Friedreich ataxia (FA) cardiomyopathy, which showed LX2006 was well tolerated with no treatment-related serious adverse events and demonstrated evidence of sustained and consistent treatment effect across multiple cardiac measures Recently initiated formal engagements with FDA on surrogate endpoints for LX2006 registrational study; expects to provide update by end of year Phase 1/2 clinical trial of LX2020 (HEROIC-PKP2) currently recruiting patients; data update from Cohort 1 on track for 2H 2024 Cash and cash equivalents of $175.0 million expected to provide operational runway into 2027 NEW YORK, Aug. 12, 2024 (GLOBE N

      8/12/24 7:00:00 AM ET
      $LXEO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care